EntryPoint Capital LLC Takes $98,000 Position in Insulet Co. (NASDAQ:PODD)

EntryPoint Capital LLC purchased a new stake in shares of Insulet Co. (NASDAQ:PODD) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 571 shares of the medical instruments supplier’s stock, valued at approximately $98,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PODD. Capital Research Global Investors increased its position in shares of Insulet by 19.7% during the 4th quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock valued at $2,056,255,000 after purchasing an additional 1,556,455 shares during the last quarter. Baillie Gifford & Co. purchased a new stake in Insulet in the 4th quarter worth approximately $263,144,000. Norges Bank purchased a new stake in Insulet in the 4th quarter worth approximately $227,655,000. Goldman Sachs Group Inc. increased its holdings in Insulet by 56.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 878,529 shares of the medical instruments supplier’s stock worth $190,623,000 after acquiring an additional 316,649 shares in the last quarter. Finally, Los Angeles Capital Management LLC increased its holdings in Insulet by 462.3% in the 1st quarter. Los Angeles Capital Management LLC now owns 299,654 shares of the medical instruments supplier’s stock worth $51,361,000 after acquiring an additional 246,364 shares in the last quarter.

Analysts Set New Price Targets

Several research firms recently issued reports on PODD. Jefferies Financial Group increased their target price on shares of Insulet from $255.00 to $260.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Raymond James cut their price objective on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a report on Friday, May 10th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $234.00 price objective on shares of Insulet in a report on Tuesday. OTR Global reaffirmed a “mixed” rating on shares of Insulet in a report on Monday, June 10th. Finally, Barclays cut their price objective on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a report on Monday, May 13th. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and a consensus target price of $239.18.

Insulet Trading Up 2.8 %

PODD traded up $5.41 during trading on Friday, reaching $196.29. The company had a trading volume of 1,134,512 shares, compared to its average volume of 836,810. The stock has a market cap of $13.75 billion, a P/E ratio of 57.84, a PEG ratio of 3.50 and a beta of 1.16. The business has a 50 day simple moving average of $193.12 and a 200-day simple moving average of $184.80. Insulet Co. has a 52 week low of $125.82 and a 52 week high of $283.00. The company has a quick ratio of 2.75, a current ratio of 3.74 and a debt-to-equity ratio of 1.72.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.34. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The business had revenue of $441.70 million for the quarter, compared to analyst estimates of $424.05 million. During the same quarter last year, the firm posted $0.23 earnings per share. The business’s revenue was up 23.3% compared to the same quarter last year. On average, equities analysts anticipate that Insulet Co. will post 3.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, SVP Mark N. Field sold 1,500 shares of the stock in a transaction on Friday, June 14th. The stock was sold at an average price of $199.96, for a total value of $299,940.00. Following the sale, the senior vice president now owns 12,875 shares in the company, valued at $2,574,485. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, SVP Mark N. Field sold 2,131 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.43, for a total transaction of $405,806.33. Following the transaction, the senior vice president now owns 14,375 shares in the company, valued at $2,737,431.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Mark N. Field sold 1,500 shares of the firm’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $199.96, for a total value of $299,940.00. Following the transaction, the senior vice president now owns 12,875 shares in the company, valued at approximately $2,574,485. The disclosure for this sale can be found here. Insiders have sold a total of 13,931 shares of company stock worth $2,636,286 over the last quarter. Company insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.